Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron T Gerds

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Leukemia & Lymphoma|July 12, 2017
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete responseCaner Saygin, Nikolaos Papadantonakis, Ryan D Cassaday, et al.
Blood Advances|September 19, 2019
Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantationBetty K Hamilton, Lisa A Rybicki, David Grove, et al.
Bone Marrow Transplantation|February 11, 2023
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucelAgrima Mian, Wei Wei, Betty K Hamilton, et al.
Bone Marrow Transplantation|October 10, 2021
Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantationPranay Hegde, Lisa Rybicki, Sheila Serafino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid CancerRemco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2019
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell TransplantationBrian T Hill, Lisa A Rybicki, Theresa A Urban, et al.
Blood Advances|November 10, 2020
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phaseVikas Gupta, James A Kennedy, Jose-Mario Capo-Chichi, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 8, 2022
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoringKelly J Gaffney, Theresa A Urban, Mariana Lucena, et al.
Leukemia|October 19, 2021
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter studySiddharth Kunte, Lisa Rybicki, Auro Viswabandya, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia VeraAlexander Coltoff, Ruben Mesa, Jason Gotlib, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Leukemia & Lymphoma|July 12, 2017
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete responseCaner Saygin, Nikolaos Papadantonakis, Ryan D Cassaday, et al.
Blood Advances|September 19, 2019
Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantationBetty K Hamilton, Lisa A Rybicki, David Grove, et al.
Bone Marrow Transplantation|February 11, 2023
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucelAgrima Mian, Wei Wei, Betty K Hamilton, et al.
Bone Marrow Transplantation|October 10, 2021
Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantationPranay Hegde, Lisa Rybicki, Sheila Serafino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid CancerRemco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2019
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell TransplantationBrian T Hill, Lisa A Rybicki, Theresa A Urban, et al.
Blood Advances|November 10, 2020
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phaseVikas Gupta, James A Kennedy, Jose-Mario Capo-Chichi, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 8, 2022
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoringKelly J Gaffney, Theresa A Urban, Mariana Lucena, et al.
Leukemia|October 19, 2021
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter studySiddharth Kunte, Lisa Rybicki, Auro Viswabandya, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia VeraAlexander Coltoff, Ruben Mesa, Jason Gotlib, et al.
Pageof 14